Document Detail

Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: a pilot study.
MedLine Citation:
PMID:  8394849     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: The study was designed to assess the feasibility of conducting a trial to investigate whether exercise and low molecular weight heparin therapy with dalteparin sodium (Fragmin) would improve collateral function to the ischemic myocardium in patients with coronary artery disease. BACKGROUND: The severity of myocardial ischemia in patients with coronary artery disease is at least partly dependent on the status of the collateral circulation. Therefore, improvement in collateral function would potentially provide a unique way of alleviating myocardial ischemia. Because the combination of ischemia and heparin has previously been demonstrated to enhance collateral growth, we studied the anti-ischemic effects of combined treatment with dalteparin sodium and exercise-induced ischemia in patients with coronary artery disease. METHODS: Twenty-three patients with stable coronary artery disease were randomized to receive either subcutaneous dalteparin sodium or placebo for a 4-week period. Patients received either placebo or 10,000 IU of dalteparin sodium by subcutaneous injection once daily for weeks 1 and 2 and 5,000 IU daily for weeks 3 and 4. During the 1st 2 weeks, patients were exercised to ischemia three times a day. At baseline and 4 weeks after treatment, treadmill exercise testing, exercise radionuclide ventriculography and 48-h ambulatory ST segment monitoring were performed. RESULTS: Eight (80%) of the 10 dalteparin sodium-treated patients compared with 4 (31%) of 13 placebo-treated patients (p < 0.02) had an increased rate-pressure product at the onset of 1 mm of ST segment depression. The duration of exercise to ischemia increased in all patients treated with low molecular weight heparin and in 62% of placebo-treated patients (p < 0.03). The number and duration of episodes of ST segment depression during ambulatory monitoring decreased by 30% and 35%, respectively (p < 0.05), in the dalteparin sodium group but were unchanged in the placebo group. The decrease in left ventricular ejection fraction with exercise was lower in 80% of dalteparin sodium-treated patients compared with 54% of placebo-treated patients (p = 0.06). When all five factors reflecting collateral function were considered together in a multivariate analysis of variance, there was a significant improvement in low molecular weight heparin-treated patients compared with placebo-treated patients (p = 0.014). CONCLUSIONS: This study provides preliminary evidence suggesting that exercise and low molecular weight heparin therapy with dalteparin sodium lessen myocardial ischemia and that the improvement is likely to be mediated by enhanced collateral function.
A A Quyyumi; J G Diodati; E Lakatos; R O Bonow; S E Epstein
Related Documents :
11398819 - Noise-induced hearing loss among u.s. air force cryptolinguists.
8394849 - Angiogenic effects of low molecular weight heparin in patients with stable coronary art...
3962859 - Usefulness of early exercise testing after non-q-wave myocardial infarction in predicti...
8183089 - Intestinal absorption during rest and exercise: implications for formulating an oral re...
16944399 - Salivary steroids at rest and after a training load in young male athletes: relationshi...
3211709 - Osmotic work across inner medullary collecting duct accomplished by difference in refle...
1968919 - Effects of oral cetirizine, a selective h1 antagonist, on allergen- and exercise-induce...
22082869 - Activation of autophagy is required for muscle homeostasis during physical exercise.
10723119 - The effects of exercise duration on post-exercise hypotension.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  22     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  1993 Sep 
Date Detail:
Created Date:  1993-09-23     Completed Date:  1993-09-23     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  635-41     Citation Subset:  AIM; IM    
Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Blood Coagulation / drug effects
Coronary Disease / blood,  diagnosis,  drug therapy*,  epidemiology
Double-Blind Method
Electrocardiography, Ambulatory / drug effects,  statistics & numerical data
Gated Blood-Pool Imaging / drug effects,  statistics & numerical data
Heparin, Low-Molecular-Weight / therapeutic use*
Middle Aged
Multivariate Analysis
Pilot Projects
Prospective Studies
Time Factors
Reg. No./Substance:
0/Heparin, Low-Molecular-Weight
Comment In:
J Am Coll Cardiol. 1994 Jul;24(1):272-4   [PMID:  7516353 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Behavioral effects of a synthetic corticotropin 4-9 analog in patients with depression and patients ...
Next Document:  The influence of prenatal exposure to different salt diets on body and organ weights in newborn Dahl...